Lars Julsrud
University of Oslo
7 Papers
10 Citations
Lars Julsrud is an academic researcher from University of Oslo. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
TL;DR: The immune response exhibited several characteristics of possible clinical significance including high IFNγ/IL-10 ratios, polyfunctional cytokine profiles, and recognition of naturally processed antigens and support the general concept of combining cancer vaccination with chemotherapy.
142
Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease.
Henning Beckstrøm,Lars Julsrud,Øyvind Haugeto,Deborah Dewar,David I. Graham,Knut P. Lehre,Jon Storm-Mathisen,Niels C. Danbolt +7 more
TL;DR: The levels of GLAST and GLT showed negative correlation in agreement with the idea that these proteins are differentially regulated, and it is concluded that Alzheimer's disease brains can have both normal and reduced levels of these proteins.
98
Multimodal functional imaging for early response assessment in GIST patients treated with imatinib
Mona-Elisabeth Revheim,Knut Håkon Hole,Øyvind S. Bruland,Edmund Reitan,Bodil Bjerkehagen,Lars Julsrud,Therese Seierstad +6 more
TL;DR: Computed tomography and the response evaluation criteria in solid tumours (RECIST) have been used for the assessment of treatment response in GIST patients, and based solely on measurements of tumour size, functional and metabolic responses are not included.
Navigation-Assisted Surgery for Locally Advanced Primary and Recurrent Rectal Cancer
Arne Mide Solbakken,Simen Sellevold,Milan Spasojevic,Lars Julsrud,H.L. Emblemsvåg,Henrik M. Reims,Olaf Sørensen,Ebbe Billmann Thorgersen,Lena Fauske,Joanna Sara Maria Ågren,Bjørn Brennhovd,T. Ryder,Stein Gunnar Larsen,Kjersti Flatmark +13 more
TL;DR: The NAVI-LARRC prospective study evaluated feasibility of navigation in patients with locally advanced primary and recurrent rectal cancer and found navigation to be feasible, and adherence to the resection plan was satisfactory.
5
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial.
N. K. Andresen,Andreas Hagen Røssevold,Claire Quaghebeur,Bjørnar Gilje,Beate Boge,Andrea Gombos,Ragnhild Sørum Falk,Randi R. Mathiesen,Lars Julsrud,Øystein Garred,Hege G. Russnes,Ragnhild Reehorst Lereim,Sudhir Kumar Chauhan,Ole Christian Lingjærde,Claire Dunn,Bjørn Naume,Jon Amund Kyte +16 more
TL;DR: The addition of ipi/nivo to chemotherapy increased toxicity without improving efficacy and a numerical PFS advantage was observed for patients with a high Treg gene signature in tumor.
4